NCT02939495已完成4 期
The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy in the Treatment of Men With Premature Ejaculation and Erectile Dysfunction (DAP-SPEED Study)
Neutec Ar-Ge San ve Tic A.Ş1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2016年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- The evaluation of change in Intra-vaginal Ejaculation Latency Time (IELT) compared to baseline.
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of Dapoxetine/Sildenafil 30/50 mg film-coated tablet in the treatment of men with premature ejaculation and erectile dysfunction.
详细描述
During 4-weeks treatment period, patients will take one Dapoxetine/Sildenafil 30/50 mg film coated tablet 1-3 hours before sexual intercourse.
Study drug should not be used more than 1 tablet every 24 hours during the treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •18-64 years old men,
- •Participants must be heterosexual males and in a stable monogamous sexual relationship with a female partner for at least 6 months and will continue throughout the study,
- •Clinical diagnosis of erectile dysfunction, IIEF score ≤21,
- •Premature Ejaculation Diagnostic Tool (PEDT) score must be ≥11
- •Patients with life-long PE and acquired PE according to the description of International Society for Sexual Medicine (ISSM) ,
- •The patient and his partner must have sexual intercourse twice a week for the duration of the study,
- •Commitment to comply with the study protocol,
- •Patients who sign informed consent form (ICF).
排除标准
- •History of medical events such as surgical interventions or neurologic conditions (e.g., multiple sclerosis), trauma, or infections that are associated with the development of symptoms of premature ejaculation (PE) and considered a potential cause of PE,
- •Having genital abnormalities, except penile curvature unless not prevent sexual intercourse,
- •Developed ED or PE due to drug use or quit taking drugs,
- •Any conditions that prevent sexual intercourse with partners
- •History of epilepsy,
- •Severe renal insufficiency,
- •Liver disease,
- •History of in last 6 months stroke, myocard infarction, cardiac insufficiency (New York Cardiovascular Associates (NYCA) phase II-IV), AV block or message disorder such as sick sinus syndrome, severe ischemic cardiac disease, syncope, unstable angına, life-threatening arrhythmia or hypotension,
- •Non-Arteritic Anterior ischemic optic neuropathy,
- •Patients who are not eligible to have sexual intercourse due to existing health problems,
- •Autonomic neuropathy, retinitis pigmentosa, blood diseases, active peptic ulcer, abnormalities in ECG, severe systemic disease that cannot be controlled,
- •Systolic/Diastolic blood pressure at rest <90/50mmHg and 170/100mmHg<
- •History of allergy to Selective Serotonine Reuptake Inhibitor (SSRI) and phosphodiesterase inhibitor drugs,
- •Continuing to use or quitted in last 3 months of Monoamine oxidase inhibitor (MAOI), Thioridazine, Serotonine Reuptake Inhibitor (SSRI), Selective-Norepinephrin Reuptake Inhibitor (SNRI), Serotonergic drug/herbal product, tricyclic antidepressant and atypical antipsychotic drugs,
- •Use of nitrates, alfa blockers, vasodilators, ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir, atazanavir, cimetidine, erithromicin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil, diltiazem, any kind of vasodilator, antiplatelet, anticoagulant, dapoxetine, PDE5 inhibitor, alcohol and stimulant drug,
- •Patients on a different therapy (behavioral therapy or other drugs that are applied locally) for PE treatment
- •During the study, the possibility of taking medication which may affect the study drug's pharmacokinetic/pharmacodynamic properties
- •Patients who are defining symptoms of prostatitis clinically
- •Thyroid hormone disorders
研究组 & 干预措施
Study drug
Experimental
Dapoxetine/Sildenafil 30/50 mg film coated tablet
干预措施: Dapoxetine/Sildenafil 30/50 mg film coated tablet (Drug)
结局指标
主要结局
The evaluation of change in Intra-vaginal Ejaculation Latency Time (IELT) compared to baseline.
时间窗: 4-weeks
The evaluation of IIEF-15 (International Index of Erectile Function Questionnaire) score compared to baseline.
时间窗: 4-weeks
The evaluation of premature ejaculation symptom scores compared to baseline.
时间窗: 4-weeks
次要结局
- The evaluation of Premature Ejaculation response measured by Premature Ejaculation Profile (PEP)(4-weeks)
- The Rate of Premature Ejaculation Profile (PEP) response(4-weeks)
- The evaluation of safety of study drug (Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment)(4-weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
The Safety of Dapoxetine/Tadalafil Combination TherapySafety IssuesErectile DysfunctionPremature EjaculationNCT03177746Neutec Ar-Ge San ve Tic A.Ş40
已完成
3 期
Evaluation of the Clinical Efficacy and Safety of Dapoxetine, Combined Dapoxetine With Folic Acid and Combined Dapoxetine With Vitamin B12 in Treatment of Patients With Premature EjaculationPremature EjaculationNCT04085354Sohag University120
尚未招募
3 期
A clinical trial to study the effects of Dapoxetine in premature ejaculation in the adult population.CTRI/2010/091/001089Sun Pharmaceutical Industries Ltd.Acme Plaza, Andheri Kurla Road, Andheri East,Mumbai ? 400059. Maharashtra. India.200
已完成
3 期
Concomitant Use of PriLigy in Men Treated for Erectile DysfunctionErectile DysfunctionSexual DysfunctionNCT01063855Johnson & Johnson Pharmaceutical Research & Development, L.L.C.495
已完成
3 期
An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid EjaculationEjaculationErectile DysfunctionSexual DysfunctionNCT01230762Alza Corporation, DE, USA1,774